The research team — led by Erping Long and Haotian Lin of Guangzhou, China-based Sun Yat-sen University — developed CC-Cruiser, an AI platform that uses deep learning to risk stratify populations for screening, diagnose patients for the disease and provide clinical support to ophthalmologists making treatment decisions.
The researchers launched a multihospital clinical trial to validate the utility of CC-Cruiser and are working to compare the AI platform’s performance with trained ophthalmologists. The team wrote that the trial will “explore the management of rare diseases and the cloud-based AI platform for providing medical suggestions for non-specialized hospitals.”
“The collaborative platform could be extended to the management of other rare diseases, and should be validated in different clinical scenarios,” they wrote.
More articles on health IT:
‘Watson for Oncology’ debuts in US
Accenture forecast: ‘AI is the new UI’
Penn Medicine uses data analytics to drive cancer-focused urgent care
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.